Hemophilia

Technique Allows New Plasma Product Testing In Broader Patient Group

Published in Blood Weekly, September 20th, 2001

by Sonia Nichols, senior medical writer - New product developers could include a broader range of individuals with hemophilia in their testing groups by incorporating a strategy developed by researchers in Sweden.

Currently, recommendations for the testing of viral safety in plasma derivatives indicates previously untreated patients (PUPs) should be used. However, a group at the University of Lund in Malmo, Sweden, has used previously treated, noninfected patients (NIPs) to test plasma derivatives, and they are claiming success.

"Several product lots can be studied in a single patient, with a study period for each lot of three months," said E....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry